Physician profile
David E Tsong
NPI 1942228739
$18,399.41
in general payments reported to CMS, 2019-2025
41 companies · $3,753 in 2025
The $3,753 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $1,021 · 2021: $1,663 · 2022: $1,928 · 2023: $3,552 · 2024: $5,542 · 2025: $3,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,846.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,952.19 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $2,309.95 | 2019-2025 | Evenity, Krystexxa, Repatha |
| Glaxosmithkline, LLC. | $2,253.66 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $948.22 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Gilead Sciences, INC. | $751.05 | 2023-2025 | Vemlidy, Epclusa |
| Lilly USA, LLC | $750.16 | 2019-2025 | Kisunla, Mounjaro, Jardiance |
| Abbvie INC. | $489.99 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $485.79 | 2019-2024 | Xarelto |
| Insulet Corporation | $440.02 | 2023-2025 | Omnipod |
| Cequr Corporation | $437.82 | 2022-2025 | Cequr Simplicity |
| Novo Nordisk INC | $377.40 | 2019-2025 | Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $375.00 | 2024-2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $364.28 | 2024 | Voquezna |
| Corcept Therapeutics | $337.68 | 2023-2024 | Korlym |
| Scilex Pharmaceuticals INC. | $277.16 | 2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $265.21 | 2023-2025 | Freestyle Libre 3 |
| Ardelyx, INC. | $250.00 | 2024-2025 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $237.20 | 2023 | Recorlev, Gvoke Hypopen |
| Pfizer INC. | $171.68 | 2019-2021 | |
| Allergan, INC. | $165.77 | 2019-2020 | |
| Dexcom, INC. | $161.51 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $152.31 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.24 | 2021-2023 | |
| Daiichi Sankyo INC. | $133.90 | 2021 | |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $121.84 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $121.44 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $119.49 | 2024 | Inpefa |
| Impel Pharmaceuticals INC. | $114.99 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $111.42 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $90.07 | 2020-2025 | Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $57.56 | 2020-2022 | |
| Exact Sciences Corporation | $50.90 | 2024-2025 | Cologuard Collection Kit |
| Nabriva Therapeutics, Plc | $30.80 | 2021 | |
| Paratek Pharmaceuticals, INC. | $24.93 | 2024 | Nuzyra |
| Redhill Biopharma INC. | $23.99 | 2020 | |
| Seqirus USA INC | $18.75 | 2019 | |
| Eisai INC. | $16.67 | 2021 | |
| Circassia INC. | $12.50 | 2019 | |
| Sanofi Pasteur INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tsong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.